Reset complete: How Elixinol Wellness is positioning for its next growth phase
In its August 2026 investor presentation, Elixinol Wellness (ASX: EXL) framed itself as a business that has completed a multi-year transformation from a legacy US CBD story into an Australian health and wellness platform, now pivoting from reset to disciplined growth.
Management pointed to a set of lead metrics: $4.3m record Q2 FY26 revenue, a 45% gross margin (up from 38% in the prior comparable period), operating expenses down 23% on the prior corresponding period, and three consecutive quarters of positive underlying operating cash flow.
The company’s central thesis is that operating performance has improved materially, yet that change has not yet been reflected in the equity story.
When big ASX news breaks, our subscribers know first
From US CBD legacy to an Australian wellness platform
The presentation outlined a strategic shift that management said unfolded over the past three years and accelerated in the last 12 months. The company described a four-stage journey.
- US CBD scale: a sizeable US CBD business shaped the original investor perception.
- Category contracts: post-COVID demand softened as US regulation became increasingly uncertain.
- Australian platform built: M&A brought together trusted brands, channels and local capability.
- Reset, then grow: margin, costs and cash discipline have been rebuilt, positioning the platform to scale again.
Management’s message was that “legacy perceptions are outdated” and that the earnings base is now “increasingly Australian, diversified and growth-ready.”
Management positioning statement
“The reset is substantially complete. The next proof point is disciplined growth.”
The presentation set out the reset commitments the company said it had delivered:
- Capital management and liquidity reset completed
- Gross margin lifted to 45%, up 3 percentage points on the prior comparable period
- Operating expenses reduced 23% on the prior corresponding period
- Three consecutive quarters of positive underlying operating cash flow
- THC earn-out restructured and Small Parcel Sale Facility completed
- National retail expansion secured across Priceline, Coles and Metcash
Margin expansion and cash discipline in the numbers
The presentation highlighted a steady improvement in gross margin across recent quarters, culminating in a record $4.3m Q2 FY26 revenue result.
| Quarter | Gross Margin |
|---|---|
| Q2-24 | 36% |
| Q3-24 | 39% |
| Q4-24 | 40% |
| Q1-25 | 37% |
| Q2-25 | 38% |
| Q3-25 | 38% |
| Q4-25 | 42% |
| Q1-26 | 45% |
| Q2-26 | 45% |
Alongside margin gains, the company detailed cost reductions across the business, all measured against the prior comparable period:
- Operating expenses: -23%
- Employee costs: -23%
- Distribution: -25%
- Marketing: -32%
- Admin and corporate: -15%
Management noted Q2 FY26 underlying operating cash flow of +$0.05m, and observed that reported cash flow for the quarter included one-off AGM costs, interest and out-of-cycle payments. The company’s framing was that margin and gross profit growing faster than sales signals an improving quality of earnings.
The four-brand platform and its lead growth engine
The presentation described a wellness platform built on four brands, each with a defined purpose:
- The Healthy Chef: women’s strength, vitality and healthy ageing
- Mt Elephant: better-for-you indulgence and family wellness
- Hemp Foods Australia: plant-based nutrition and ingredient credibility
- B2B Ingredients: nature-led innovation, private label and B2B growth
Management described EXL as “Australia’s largest hemp foods company”, positioning it as a vertically integrated platform. The company noted 2 major grocery retailers are supplied under contracted arrangements with partners, with existing supply contracts extending to 2027.
The Healthy Chef was flagged as the emerging core growth engine:
- $1.15m Q2 FY26 revenue
- 27% of Group revenue
- +20% versus the prior comparable period, and +26% versus Q1 FY26
- Priceline Stage 1 rollout across approximately 410 stores
The Priceline national rollout is structured across two stages, with Stage Two targeting broader store penetration and range extensions in early 2027 subject to Stage One performance, marking a deliberate shift from The Healthy Chef’s direct-to-consumer origins.
Why healthy ageing and the GLP-1 wave matter
The presentation set out the category tailwinds management is targeting. According to figures cited from the Global Wellness Institute (2025), the global wellness economy was valued at US$6.8tn in 2024 and is projected to reach US$9.8tn by 2029. The company also referenced McKinsey research (Future of Wellness Trends Survey 2025) indicating up to 60% of consumers consider healthy ageing a top or very important priority.
Management argued that rising awareness is creating a wider “GLP-1 curious” and “peptide curious” market, where consumers seek everyday support for metabolism, satiety, protein intake and muscle maintenance without pharmaceutical involvement.
The company positioned its portfolio as a credible entry point into this demand, moving from Protein Waters to Metabolic Burn and then to Nutritional Peptides covering sleep, muscle and expanded weight management. The stated aim is to target long-term consumer demand.
Growth engines and the execution roadmap
Management outlined four practical growth engines underpinning the strategy:
- Product innovation: build around protein, healthy ageing, convenience and better-for-you indulgence
- Channel expansion: scale through ecommerce, grocery, pharmacy, health food and B2B
- Operating discipline: protect margin, share capability and allocate capital carefully
- Selective acquisition: add aligned brands or capabilities that strengthen the platform
The presentation flagged several proof points management expects to demonstrate execution over the next 6 to 12 months:
- Retail: Priceline rollout and broader pharmacy awareness
- Grocery: Mt Elephant national expansion and new formats
- Innovation: functional nutrition and nutritional or bioactive peptide pipeline
- Portfolio: continued mix improvement and B2B opportunities
- Capital: disciplined assessment of aligned acquisitions
The valuation disconnect management is pointing to
The presentation closed on a re-rating thesis, framing the current valuation as a low starting point relative to improving fundamentals. As at 6 August 2026, the company cited a market capitalisation of A$2.9m, based on A$0.007 per share and 413.99m shares on issue.
Against A$15.7m in L12M revenue and A$6.7m in L12M gross profit, management pointed to a market cap to revenue multiple of 0.18× (for the last 12 months ending 30 June 2026).
Management valuation framing
“The disconnect is the opportunity: operating performance has changed, but the upside potential has not yet been priced in.”
Management’s argument is that consistent growth, sustained margins and continued cash discipline can progressively reshape how the market values EXL.
For investors exploring the mechanics behind the balance sheet restructuring, our detailed coverage of EXL’s capital reset strategy walks through the convertible note structure, AGM share approval, and the Mt Elephant grocery rollout that together underpinned the transition to back-to-back positive cash flow.
The company summarised its positioning under the banner “Live Well | Live Strong | Age Better”, describing an intention to build a scalable wellness platform in categories supported by long-term consumer demand.
Don’t Miss the Next Consumer Wellness Winner
Big News Blast delivers FREE breaking ASX news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000+ subscribers rely on it to stay ahead of market-moving announcements across Consumer, Healthcare, Tech and more. Click the “Free Alerts” button to start receiving alerts the moment news breaks.